Prostate Services and Procedures and Impotence Treatment – Medicare Advantage Medical Policy | UHC Coverage Update

TL;DR: UnitedHealthcare modified its prostate services and procedures coverage policy, effective December 2, 2025. Here's what billing teams need to know about the changes to CPT 37243, 52441, 52442, 53855, 55899, 64999, and HCPCS L8699.

UnitedHealthcare updated its policy covering prostate services, procedures, and impotence treatment, with an effective date of December 2, 2025. This policy change clarifies coverage guidelines for several prostate interventions under Medicare Advantage — including prostatic urethral lift (PUL), prostate artery embolization (PAE), temporary prostatic stenting, and nerve graft procedures. The real issue here is how UHC handles the gap between Medicare's general NCD framework and procedure-specific medical necessity criteria — and how that gap creates claim denial risk if your billing team isn't aligned with the right policy document for each service.

Quick-Reference Table

UnitedHealthcare Prostate Services Coverage Criteria and Medical Necessity Requirements 2025

The central structure of this UnitedHealthcare coverage policy is a series of redirects. For most procedures covered here, UHC explicitly defers to its Commercial Medical Policy titled Prostate Surgeries and Interventions for the actual coverage guidelines. That might sound simple, but it creates a real workflow problem: your billing team needs to cross-reference a second policy document to confirm medical necessity before submitting a claim.

Here's how each procedure sits within the Medicare Advantage framework:

Temporary Prostatic Stent (CPT 53855): Medicare has no National Coverage Determination (NCD) and no Local Coverage Determination (LCD) or Local Coverage Article (LCA) for temporary prostatic stents — including devices like the Spanner® and Memokath™. Coverage guidelines fall entirely under the UHC Commercial Medical Policy for Prostate Surgeries and Interventions. If you bill CPT 53855 for UHC Medicare Advantage members, that commercial policy is your medical necessity benchmark.

Prostatic Urethral Lift / UroLift® System (CPT 52441, 52442, HCPCS L8699): Same structure. No Medicare NCD, no LCD, no LCA. UHC's Commercial Medical Policy for Prostate Surgeries and Interventions governs coverage. CPT 52441 covers insertion of the first permanent adjustable transprostatic implant via cystourethroscopy. CPT 52442 covers each additional implant placed in the same session. HCPCS L8699 applies to the prosthetic implant itself. Make sure your charge capture reflects both the procedural codes and the device code — missing L8699 leaves reimbursement on the table.

Nerve Graft to Restore Erectile Function During Radical Prostatectomy (CPT 55899, 64999): No Medicare NCD, LCD, or LCA exists for this procedure either. Coverage guidelines come from a separate, dedicated UHC Commercial Medical Policy specifically titled Nerve Graft to Restore Erectile Function During Radical Prostatectomy. These are unlisted procedure codes — CPT 55899 for the male genital system and CPT 64999 for the nervous system — which means prior authorization and detailed operative documentation are not optional. They're essential.

Prostate Artery Embolization / PAE (CPT 37243): This is the most complex piece of this coverage policy. Medicare does have a general NCD for Therapeutic Embolization (NCD 20.28). However, no LCD or LCA exists specifically for PAE. UHC supplements NCD 20.28 with its own criteria from the Prostate Surgeries and Interventions Commercial Medical Policy to determine when PAE is reasonable and necessary for treating BPH-related lower urinary tract symptoms (LUTS).

UHC's rationale here is worth understanding. Untreated benign prostatic hyperplasia (BPH) can progress to chronic high-pressure retention — a potentially life-threatening condition. Untreated bladder outlet obstruction (BOO) can cause urinary dysfunction, acute urinary retention (AUR), or kidney injury. UHC uses its supplemental criteria to create consistency in coverage decisions and reduce both inappropriate denials and inappropriate approvals. The policy is explicit about the clinical harms of getting this wrong in either direction.

If PAE is incorrectly denied, patients may end up with alternative treatments, increased urinary incontinence, worsening bladder function (which can become permanent), inflamed prostate, urinary tract infections, urethral stricture, bladder stones, kidney stones, gross hematuria, or renal insufficiency. If PAE is incorrectly approved for the wrong patient, the risks include blood in the urine, semen, or stool, puncture site bleeding, bladder spasm, infection, dysuria, hematospermia, diarrhea, and post-embolization syndrome. Bill CPT 37243 for PAE under UHC Medicare Advantage, and make sure your documentation maps to both NCD 20.28 criteria and UHC's supplemental criteria simultaneously.

Impotence-Related Prosthetics and Devices: For this category, UHC redirects entirely to its Medicare Advantage Medical Policy for Durable Medical Equipment (DME), Prosthetics, Orthotics (Non-Foot Orthotics), Nutritional Therapy, and Medical Supplies. If your practice bills impotence-related prosthetics for UHC Medicare Advantage members, confirm you're referencing that DME policy — not this one — for coverage and prior authorization guidance.

Coverage Indications at a Glance

UnitedHealthcare Prostate Services Billing Guidelines and Action Items 2025

This policy change is a documentation and routing problem as much as a coding problem. The real risk is billing teams pulling the wrong policy document when building a prior authorization or supporting a claim. Here's what to do before December 2, 2025:

CPT and HCPCS Codes for Prostate Services and Procedures Under This UHC Policy

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Unlisted Procedure Codes (Require Detailed Documentation and Prior Authorization)

HCPCS Device Code

Note: No ICD-10 codes are specified in this UHC policy document. Diagnosis code selection should align with the clinical indications documented in the referenced Commercial Medical Policies.